About Event
2025 is the Year of the Extra-Hepatic Delivery Vehicle!
You have stepped into the future of nanoparticle-based delivery at the 4th Annual Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit, where extra-hepatic delivery takes center stage. With a faculty that's 90% new speakers and 50% of companies speaking for the first time, this summit offered the latest data on the cutting-edge delivery systems in the field.
This year's event was all about innovating beyond the liver, showcasing new technologies, strategies, and case studies aimed at bypassing liver accumulation and achieving precise delivery to extra-hepatic organs. You heard from leaders like Novo Nordisk, Corti Therapeutics, Orbital Therapeutics, Northwestern University, CybernaX Bio, Strike Pharma, and MIT, sharing their most recent developments in active targeting systems, PEG-free formulations, and AI-driven nanoparticle design for more effective and targeted delivery of nucleic acids and gene-editing payloads.
You have reshaped the landscape of therapeutic delivery, whether you're focused on lipid chemistry, immunogenicity, or overcoming the limitations of traditional formulations, this event gave you the tools and insights to increase your delivery efficiency and stay ahead of the curve.
No liver, only killer… innovations for extra-hepatic delivery!
Reasons You Couldn’t Miss the Event:
Companies Spoke On The Program:
What Your Peers Had To Say:
“Non-viral delivery technology will have a major impact on future DNA and RNA-based therapies. We are at the beginning of the RNA-based therapeutic revolution in medicine. The meeting is a great opportunity to discover the latest advancements on non-viral delivery vectors. The meeting will take stock of the lipid-based technologies and bring together groundbreaking delivery strategies for developing more effective RNA/DNA-based therapeutics and beyond”
Gilles Divita, Chief Executive Officer, Aanastra/Divincell
“I am excited to present our research on a combinatorial-designed platform utilizing polymeric nanoparticles for the targeted delivery of nucleic acid therapeutics. My presentation will cover the development of formulations, as well as the in vitro and in vivo results we have obtained, with a focus on treating cancer and inflammatory diseases. The rational design of these nano-formulations is crucial for the clinical and commercial translation of these emerging therapeutic strategies, ultimately aiming to create products that can significantly benefit patients”
Nahal Habibi, Senior Scientist, Non-Viral Delivery, Orbital Therapeutics